Complete response observed and ongoing in a patient with multiply relapsed/refractory diffuse large B cell lymphoma (DLBCL) Dual BTK degradation...
PETACH TIKVA, Israel, Oct. 26, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company...
Saturn-2 follow-up data to be presented on TP-03 for the treatment of Demodex blepharitis Tarsus recently submitted NDA to the...
Atlanta, GA, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Streamline Health Solutions, Inc. (“Streamline” or the “Company”) (Nasdaq: STRM), a leading...
Yale Spinout Moves Closer Toward IND-enabling StudiesNEW HAVEN, Conn., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Modifi Biosciences, a leader in...
-- Rhythm to review data on webcast conference call on November 2, 2022 at 8:30 a.m. ET – -- Rhythm...
Study Design EnACT Phase 2 DesignTwo-week survival in Cohort 4 (all-oral regimen) was 95% in 40 patients receiving MAT2203 Mean...
BEDMINSTER, N.J., Oct. 21, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the...
SAN DIEGO, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of...
Webinar will focus on the unmet medical need in HIV, therapeutic applications of gene delivery and editing for treatment of...
SCYNEXIS is announcing a new strategic direction to refocus its resources on the clinical development of ibrexafungerp for severe, hospital-based...
Agreement will allow researchers to streamline development of on-demand and automated production of CRISPR-Cas9 guide RNASAN DIEGO, Oct. 19, 2022...
SAN FRANCISCO, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein...
SEATTLE, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune...
WILMETTE, Ill., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary...
BEDMINSTER, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused...
Two Breckenridge Staples Launch Second Annual Buddy Pass, Limited-Edition Whiskey and Beer Across the U.S. The Second Annual Buddy Pass,...
Oslo, Norway, 18 October 2022 Vistin Pharma ASA will release its third quarter and YTD 2022 results on Wednesday 26th of...
Phase 1 Study Will Include Biomarker Selected Patients with Advanced Solid TumorsWILMINGTON, Del., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Prelude...
Clinical collaboration with AstraZeneca announced for the evaluation of osimertinib in combination with IK-930 for patients with EGFR-mutant lung cancers...